Posted by Michael Wonder on 27 Feb 2017
Johnson & Johnson lifts lid on drug pricing data, shows 3.5% net hike in 2016
27 February 2017 - Johnson & Johnson, the world's largest health care company, issued a new report Monday detailing data on its medicines' price increases.
The message: We've been responsible, but the public hasn't been able to tell because of lack of transparency.
The report, which J&J says it plans to issue annually, comes as the pharmaceutical industry has once again become a national target for its pricing practices. And the message, that there's more to pricing than meets the eye, has been the industry's primary response — a response most visibly employed by Mylan Chief Executive Heather Bresch amid controversy over pricing of the EpiPen.
